Thus, the adoption of biomarker-informed treatments blocking IL-1β seems bound to significantly improve the clinical outcome of prostate cancer and other tumors, as shown by recent clinical trials with metastatic breast cancer patients [225]. Here, IL1B is linked to Familial prostate cancer.